The National Cancer Institute's Phase 0-I-II Prevention Clinical Trials Program (Consortia) performs early phase clinical trials to assess the safety, tolerability, and cancer preventive potential of agents and interventions of varying classes, many of which target molecules or processes known to be important during carcinogenesis.
The Cancer Data Access System (CDAS) is a web portal that facilitates access to the data recorded for the 2012 Consortia trials For some studies biospecimens may also be available. CDAS provides extensive public documentation for each study, including a trial summary, an overview of the data collected, and a searchable database of research projects and publications.
COVID-19 Memorandums for Division of Cancer Prevention Investigators
- COVID Minor Deviation Reporting Form (
XLS, 74 KB)
Date: May 8, 2020
- Additional Guidance Regarding Reporting of Minor Deviations for Clinical Trials Supported by the NCI DCP Phase 0-2 Cancer Prevention Clinical Trials Program (PDF, 90 KB)
Date: March 27, 2020
- Interim Guidance for Patients on Clinical Trials Supported by the NCI DCP Phase 0-2 Cancer Prevention Clinical Trials Program (PDF, 84 KB)
Date: March 13, 2020
PLEASE NOTE: This is a reminder that infections occurring in subjects on clinical trials are considered adverse events, please see this additional guidance for reporting COVID-19 related adverse event.
DCP/PREVENT-funded Project Presentations at AACR Virtual Annual Meeting I, April 9-15 2021
NCI participated in the American Association for Cancer Research (AACR) Annual Meetings 2021, held virtually on April 9 - 15, 2021, including presenting research results from PREVENT and Early Phase Clinical Projects.
PREVENT and DCP-funded Early Phase Clinical Projects’ Results Presented at AACR Virtual Annual Meetings 2020 I & II
NCI participated in the American Association for Cancer Research (AACR) Annual Meetings 2020, held virtually on April 27 - 28, 2020 (Meeting I) and June 22 - 24, 2020 (Meeting II), including presenting the following research results from PREVENT and Early Phase Clinical Projects.